Thus, the higher expression of PNPLA2 in PRDX6−/− mice may enhance the hydrolysis of triglycerides, increasing FFA blood levels, the risk of its accumulation in the liver, and the development of NAFLD. Here, PNPLA2 is linked to metabolic dysfunction-associated steatotic liver disease.